Capital Markets Day

Summary by AI BETAClose X

ECO Animal Health hosted a Capital Markets Day on 11 November 2026 presenting a risk-adjusted sum-of-the-parts enterprise valuation for ECOVAXXIN® MS and its R&D portfolio of c. £100m and an indicative valuation range for PRRSvmAb of £0–£100m dependent on a near-term key trial; ECOVAXXIN® MS was commercially launched in the EU in July 2026, the company has an exclusive in-licensing agreement with Vaxinano for a sheep toxoplasmosis vaccine candidate, management reiterated a self-funded R&D model and resilient core business, and no new material disclosures were made at the event.

Disclaimer*

UK 100

Latest directors dealings